Ayesha Jameel, MD
Endocrinology, Diabetes & Metabolism · Tacoma, WANPI 1013399856
Payments from drug & device makers
Across 502 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AstraZeneca$858
- Dexcom, Inc.$616
- Amgen$591
- Xeris Pharmaceuticals, Inc.$486
- plus $3K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 112 | $1,776 |
| Lilly USA, LLC | 53 | $1,031 |
| AstraZeneca(2 entities) | 53 | $858 |
| Dexcom, Inc. | 32 | $616 |
| Amgen | 31 | $591 |
| Xeris Pharmaceuticals, Inc. | 25 | $486 |
| Sanofi-aventis U.S. LLC | 25 | $429 |
| Boehringer Ingelheim | 25 | $407 |
| AbbVie | 21 | $387 |
| Insulet Corporation | 13 | $244 |
| Bayer | 14 | $218 |
| Zealand Pharma US, Inc. | 13 | $203 |
| Novartis | 8 | $153 |
| Abbott | 8 | $149 |
| IBSA Pharma Inc. | 8 | $146 |
| Medtronic | 8 | $140 |
| Mannkind Corporation | 9 | $139 |
| Recordati_rare_diseases_inc. | 6 | $122 |
| Corcept Therapeutics | 4 | $120 |
| Tandem Diabetes Care, Inc. | 5 | $100 |
| Pfizer | 5 | $100 |
| Merck | 7 | $100 |
| Amarin Pharma, Inc. | 4 | $63 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| Ascendis Pharma Endocrinology Inc | 2 | $33 |
| Lexicon Pharmaceuticals, Inc. | 1 | $30 |
| Amryt Pharma Holdings Ltd | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| RGH Enterprises LLC | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Cequr Corporation | 1 | $15 |
How this compares
$8,832 in reported general payments places this provider in the 70th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Tacoma
- Ronald GrafTacoma$478K
- Gabriela Loperena OropezaTacoma$12K
- Rebecca OverTacoma$6K
- Rani KulkarniTacoma$3K
- Ronald BrazgRenton$17.9M
- Frances BroylesSeattle$5.6M
- Leslie KlaffRenton$2.8M
- Carla GreenbaumSeattle$2.6M
- Irl HirschSeattle$2.4M
- William HagopianSeattle$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.